Product Images Pregabalin

This is the packaging information for Exelan, a medication containing 100 mg of pregabalin per capsule. The package includes 90 capsules and a medication guide for patients. The recommended dosage can be found on the package insert. The medication is child-resistant and should be stored between 20° to 25° G. Exelan is manufactured by InvaGen Pharmaceuticals and distributed by Exelan Pharmaceuticals in Boca Raton, Florida.*

This is a package of 90 capsules of pregabalin, each containing 160 mg, manufactured by Exelan Pharmaceuticals, Inc. The package is child-resistant and should be kept out of reach of children. The capsules should be stored at 20°C to 25°C. The prescribing information is available separately for each patient.*

This is a description of a medication called Exelan which contains 90 capsules. Each capsule has 200mg of pregabalin in it. There's a warning to keep it away from children as it's child-resistant. The medicine should be stored at a temperature between 20 to 25-degree Celsius. It is manufactured by InvaGen Pharmaceuticals, Hauppauge, NY 11788, a subsidiary of Cipla Ltd. and is distributed by Exelan Pharmaceuticals, Boca Raton, FL 33432. The package insert will provide the necessary information about the dosage.*

This is a medication package containing 90 capsules of Pregabalin, with each capsule measuring 225 mg. The package is child-resistant and should be kept out of reach of children. The medication should be stored between 20° to 25° G (68° 0 77°F) at USP Controlled Room Temperature. The manufacturer is Invagen Pharmaceuticals, which is a subsidiary of Cila Ltd. The medication has been provided separately for each patient. The distributor is Exelan Pharmaceuticals in Boca Raton, FL. The text also contains product codes, but no further information is available.*

This is a medication label for Pregabalin capsules containing 25 mg, manufactured by InvaGen Pharmaceuticals Inc. and distributed by Exelan Pharmaceuticals, Inc. The capsules are available in a child-resistant package and come with a medication guide provided separately for each patient. The package also provides dosage and storage instructions along with the manufacturer and distributor details.*

This is a description for a medication with the NDC code 76282-575-90. The medication comes in capsule form with each capsule containing 300mg of pregabalin. The packaging is child-resistant and should be kept out of reach of children. The medication should be stored at a temperature of 20° to 25° C. The manufacturer is JnyaGen Pharmaceuticals, Inc. and the medication is provided separately to each patient. The medication is for prescription only and there are 90 capsules in each package.*

This is a description of Pregabalin C Capsules, a medication that is only available with a prescription. Each capsule contains 50 g of pregabalin, USP. The recommended dosage should be reviewed in the package insert. The package is child-resistant, and should be kept out of reach of children. The medication should be stored at a controlled room temperature between 20° to 25° G (68° to 77°F). It is manufactured by InvaGen Pharmaceuticals, Inc., a subsidiary of Cipla Ltd., and sold by Exelan Pharmaceuticals, Inc. of Boca Raton, FL.*

This is a medication package for Pregabalin C Capsules containing 90 capsules with 75 mg of pregabalin USP in each capsule. It includes a medication guide to pharmacist for dispensing instructions. The package is child-resistant and should be kept out of reach of children. The manufacturer is InvaGen Pharmaceuticals and it is distributed by Exelan Pharmaceuticals. Usual dosage is subject to the information provided in the package insert. Store at controlled room temperature (20-25°C or 68-77°F).*

The text is providing information about the percentage improvement in pain from baseline for patients taking Pregabalin 160 mg free for the 3 day period. The improvement percentages are listed as 100, 2, and 10. However, the format and clarity of the text is poor, making it difficult to interpret the meaning of other information presented in the text. Not available.*

This text appears to be a chart or graph displaying percent of patients improved and percent improvement in pain from a baseline for different medications. The medications listed are Pregatalin, Pregabain, and Pregabalin, with varying dosages and frequencies. However, the chart seems incomplete or cut off, as there are no axis labels or other identifying information. Therefore, the usefulness of this text is limited and it may be better to seek additional information or a more complete version of the chart.*

This appears to be a chart or table showing the dosages of two medications (fregabalin and pregataiin) and a placebo. The chart also includes numbers indicating the percentage of patients who improved while taking each medication or placebo, as well as a graph showing the percentage improvement in pain from baseline. Without further context or information, it is unclear what condition these medications were being used to treat.*

The text provides a chart displaying the percentage of patients who have experienced improvement in pain from baseline while taking Pregabalin at different doses compared to a placebo. It is not possible to provide further description as there is not enough context or information provided.*

The text appears to be a graph showing the percentage of subjects without LTR for a drug called Progabain compared to a placebo over a period of 180 days. The percentages are listed on the Y-axis ranging from 0-100% with increments of 10%. The X-axis shows the timeline in days, from 0-180 with increments of 20 days. However, without more context, it is difficult to further interpret the data or its significance.*

The text describes a table that shows the percentage of subjects improved after 16 weeks of treatment. The table has two columns, one for pregabalin and one for placebo. The percentages range from 100 to 280, and there are values at intervals of 10 between 210 and 270. The text does not provide further information about the context or condition being treated.*

This appears to be a calculation utilized for determining the estimated glomerular filtration rate (eGFR), which is an indicator of kidney function. The formula involves subtracting the individual's age (in years) multiplied by 140 from their weight (in kilograms) and then multiplying the result by the individual's serum creatinine levels (in milligrams per deciliter). The result is then multiplied by 0.85 for female patients.*